Lassa fever
MONDO:0005820A viral hemorrhagic fever that is caused by the Lassa virus, which is transmitted by contact with infected rodents; it is characterized by fever, headache, malaise, myalgia, and hearing loss.
Also known as: LF, Lassa hemorrhagic fever
10 clinical trials for this condition and its sub-types, 7 tagged with Lassa fever itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Lassa fever vaccine candidate put to the test
Vaccine Recruiting nowLassa fever is a severe viral illness common in West Africa, and no effective treatment exists. Researchers are testing a new vaccine candidate called MOPEVAC-Las in 72 healthy adults aged 18 to 55. The trial compares three different doses of the vaccine to a placebo, given as tw…
Phase 1 • Sponsor: Institut Pasteur • Aim: Vaccine
Last updated Oct 15, 2026 00:00 UTC
-
Supercharged donor cells take on viruses after transplant
Disease control Recruiting nowThis study tests whether specially grown donor immune cells (viral-specific T-cells) can safely treat viral infections that often occur after a stem cell transplant. These infections can be serious and sometimes don't respond to standard antiviral drugs. The approach aims to boos…
Phase 1/2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can donor cells stop viruses after transplant?
Disease control Recruiting nowThis study tests whether giving patients donor-derived immune cells (VSTs) on a regular schedule can prevent dangerous viral infections after a stem cell transplant. 180 participants will be randomly assigned to receive VSTs either on a fixed schedule or only when a virus is dete…
Phase 2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Massive west african trial takes on deadly lassa fever with new drug cocktail
Disease control Recruiting nowThis large clinical trial in West Africa is testing several drugs—including favipiravir, ribavirin, dexamethasone, and a new drug called ARN-75039—to find a better treatment for Lassa fever, a viral disease that kills thousands each year. The study will enroll about 1,755 hospita…
Phase 2/3 • Sponsor: Irrua Specialist Teaching Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC